Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study
Giorgio Vittorio Scagliotti, Vera Hirsh, Salvatore Siena, David H Henry, Penella J Woll, Christian Manegold, Philippe Solal-Celigny, Gladys Rodriguez, Maciej Krzakowski, Nilesh D Mehta, Lara Lipton, José Angel García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor-Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs, Giorgio Vittorio Scagliotti, Vera Hirsh, Salvatore Siena, David H Henry, Penella J Woll, Christian Manegold, Philippe Solal-Celigny, Gladys Rodriguez, Maciej Krzakowski, Nilesh D Mehta, Lara Lipton, José Angel García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor-Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs
Abstract
Introduction: Denosumab, a fully human anti-RANKL monoclonal antibody, reduces the incidence of skeletal-related events in patients with bone metastases from solid tumors. We present survival data for the subset of patients with lung cancer, participating in the phase 3 trial of denosumab versus zoledronic acid (ZA) in the treatment of bone metastases from solid tumors (except breast or prostate) or multiple myeloma.
Methods: Patients were randomized 1:1 to receive monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg. An exploratory analysis, using Kaplan-Meier estimates and proportional hazards models, was performed for overall survival among patients with non-small-cell lung cancer (NSCLC) and SCLC.
Results: Denosumab was associated with improved median overall survival versus ZA in 811 patients with any lung cancer (8.9 versus 7.7 months; hazard ratio [HR] 0.80) and in 702 patients with NSCLC (9.5 versus 8.0 months; HR 0.78) (p = 0.01, each comparison). Further analysis of NSCLC by histological type showed a median survival of 8.6 months for denosumab versus 6.4 months for ZA in patients with squamous cell carcinoma (HR 0.68; p = 0.035). Incidence of overall adverse events was balanced between treatment groups; serious adverse events occurred in 66.0% of denosumab-treated patients and 72.9% of ZA-treated patients. Cumulative incidence of osteonecrosis of the jaw was similar between groups (0.7% denosumab versus 0.8% ZA). Hypocalcemia rates were 8.6% with denosumab and 3.8% with ZA.
Conclusion: In this exploratory analysis, denosumab was associated with improved overall survival compared with ZA, in patients with metastatic lung cancer.
Source: PubMed